This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Min, J. Articles by Alexander, S. Search for Related Content PubMed PubMed Citation Articles by Min, J. Articles by Alexander, S.

---

DNA Damage and Cellular Stress Responses

Sphingosine-1-Phosphate Lyase Regulates Sensitivity of Human Cells to Select Chemotherapy Drugs in a p38-Dependent Manner

¹ Division of Biological Sciences, University of Missouri, Columbia, Missouri; ² Katholieke Universiteit Leuven, Departement Moleculaire Celbiologie, Afdeling Farmakologie, Leuven, Belgium; and ³ Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Requests for reprints: Stephen Alexander, Division of Biological Sciences, University of Missouri, 303 Tucker Hall, Columbia, MO 65211-7400. Phone: 573-882-6670; Fax: 573-882-0123. E-mail: alexanderst{at}missouri.edu

Resistance to cisplatin is a common problem that limits its usefulness in cancer therapy. Molecular genetic studies in the model organism Dictyostelium discoideum have established that modulation of sphingosine kinase or sphingosine-1-phosphate (S-1-P) lyase, by disruption or overexpression, results in altered cellular sensitivity to this widely used drug. Parallel changes in sensitivity were observed for the related compound carboplatin but not for other chemotherapy drugs tested. Sensitivity to cisplatin could also be potentiated pharmacologically with dimethylsphingosine, a sphingosine kinase inhibitor. We now have validated these studies in cultured human cell lines. HEK293 or A549 lung cancer cells expressing human S-1-P lyase (hSPL) show an increase in sensitivity to cisplatin and carboplatin as predicted from the earlier model studies. The hSPL-overexpressing cells were also more sensitive to doxorubicin but not to vincristine or chlorambucil. Studies using inhibitors to specific mitogen-activated protein kinases (MAPK) show that the increased cisplatin sensitivity in the hSPL-overexpressing cells is mediated by p38 and to a lesser extent by c-Jun NH₂-terminal kinase MAPKs. p38 is not involved in vincristine or chlorambucil cytotoxicity. Measurements of MAPK phosphorylation and enzyme activity as well as small interfering RNA inhibition studies show that the response to the drug is accompanied by up-regulation of p38 and c-Jun NH₂-terminal kinase and the lack of extracellular signal-regulated kinase up-regulation. These studies confirm an earlier model proposing a mechanism for the drug specificity observed in the studies with D. discoideum and support the idea that the sphingosine kinases and S-1-P lyase are potential targets for improving the efficacy of cisplatin therapy for human tumors.

This article has been cited by other articles:

				N. Van Driessche, H. Alexander, J. Min, A. Kuspa, S. Alexander, and G. Shaulsky Global transcriptional responses to cisplatin in Dictyostelium discoideum identify potential drug targets PNAS, September 25, 2007; 104(39): 15406 - 15411. [Abstract] [Full Text] [PDF]

				J. Min, A. Mesika, M. Sivaguru, P. P. Van Veldhoven, H. Alexander, A. H. Futerman, and S. Alexander (Dihydro)ceramide Synthase 1 Regulated Sensitivity to Cisplatin Is Associated with the Activation of p38 Mitogen-Activated Protein Kinase and Is Abrogated by Sphingosine Kinase 1 Mol. Cancer Res., August 1, 2007; 5(8): 801 - 812. [Abstract] [Full Text] [PDF]

				B. Oskouian, P. Sooriyakumaran, A. D. Borowsky, A. Crans, L. Dillard-Telm, Y. Y. Tam, P. Bandhuvula, and J. D. Saba Sphingosine-1-phosphate lyase potentiates apoptosis via p53- and p38-dependent pathways and is down-regulated in colon cancer PNAS, November 14, 2006; 103(46): 17384 - 17389. [Abstract] [Full Text] [PDF]

				T. K. Choueiri, T. Mekhail, T. E. Hutson, R. Ganapathi, G. E. Kelly, and R. M. Bukowski Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer Ann. Onc., May 1, 2006; 17(5): 860 - 865. [Abstract] [Full Text] [PDF]

				R. L. Chisholm, P. Gaudet, E. M. Just, K. E. Pilcher, P. Fey, S. N. Merchant, and W. A. Kibbe dictyBase, the model organism database for Dictyostelium discoideum Nucleic Acids Res., January 1, 2006; 34(suppl_1): D423 - D427. [Abstract] [Full Text] [PDF]